A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 159 (3) , 827-838
Abstract
No abstract availableKeywords
Funding Information
- Changzhou Qianhong Biopharmaceuticals Co Ltd.
- Changzhou LeSun Pharmaceuticals Ltd
- Australia Government National Health and Medical Research Council (1135682)
- Commonwealth Government Research Training Program Scholarship
This publication has 39 references indexed in Scilit:
- Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosisCell Division, 2013
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer CellsCancer Cell, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerClinical Cancer Research, 2011
- Cyclin D1 predicts the prognosis of advanced serous ovarian cancerExperimental and Therapeutic Medicine, 2011
- Preclinical model of organotypic culture for pharmacodynamic profiling of human tumorsProceedings of the National Academy of Sciences, 2010
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant CancersCancer Research, 2009
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancerOncogene, 2007
- Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil GranulocytesMolecular and Cellular Biology, 2006